Imlifidase is administered before a kidney transplant to avoid rejection of the donated organ by the immune system. Credit: Robina Weermeijer on Unsplash.

The UK National Institute for Health and Care Excellence (Nice) has recommended Hansa Biopharma’s imlifidase (Idefirix) for the desensitisation of highly sensitised adults before kidney transplant from a deceased donor.

An enzyme, imlifidase is administered before a kidney transplant to avoid rejection of the donated kidney by the immune system. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It acts by disintegrating a type of antibody called immunoglobulin G (IgG), which aids in protecting the body against foreign or harmful substances.

The treatment is intended for people who are greatly sensitised to human leukocyte antigens (HLAs) to prevent the body from rejecting the donor organ.

HLAs play an important role in the immune system’s response to foreign substances.

See Also:

Individuals who are greatly sensitive to HLAs are at increased risk of their kidney transplant being rejected due to the response of the immune system to the surgery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With the latest development, more than 100 individuals in England and Wales will be eligible to receive imlifidase.

The recommendation is based on considering the treatment’s cost-effectiveness, clinical efficacy and the substantial unmet need of the patients it serves.

NICE Centre for Health Technology Evaluation medicines evaluation interim director Helen Knight said: “People who are highly sensitised to HLAs can often be waiting a long time for a kidney transplant. 

“They are often on dialysis, and this can have a significant impact on their quality of life.

“Imlifidase gives people a greater chance of having a successful kidney transplant and a better quality of life in future.”

Prior to this development, NICE recommended Amarin’s icosapent ethyl (Vazkepa) to lower the risk of cardiovascular events in adults with elevated levels of triglycerides.